Journal of Clinical Lipidology

Article	Citations
A Single-Dose, Four-way-Crossover Comparative Bioavailability Study of Two Omega-3 Formulations under Fasting and Fed Conditions in Healthy Volunteers	112
Treatment Gap in Prevention of Myocardial Infarction in Rural New York State	101
News from NLA	100
Genetic Testing for Hypertriglyceridemia in Academic Lipid Clinics - Implications for Precision Medicine	93
The Effect of Estrogen and Testosterone on Cholesterol Crystallization	58
Prevalence of Lipoprotein(a) Measurements in Patients with or at Risk of Cardiovascular Disease	54
Evidence of Direct Hepatic Secretion of Low density Lipoprotein (LDL) in Mice	52
†Role of DNA methylation on 15-Lipoxygenase-1 gene expression in Osteoarthritis	51
Lower Activity of Cholesteryl Ester Transfer protein (CETP) and the Risk of Dementia: A Mendelian Randomization Analysis	49
Multi-pathway cholesterol depletion on top of FOLFIRINOX in newly-diagnosed metastatic pancreatic adenocarcinoma	47
Comparison of virtual vs face-to-face medical nutrition therapy in patients with hyperlipidemia	44
From the Editors: New insights into lipid disorders in children and adolescents as well as cardiovascular benefits of pharmacotherapy for weight loss	41
Mesenchymal Stromal Cell (MSC) Therapy Improve Nonalcoholic Fatty Liver Disease (NAFLD) in Long Term high Fat Diet (HFD) Induced Obesity (DIO) Mouse	40
Lipoprotein(a) levels in children with homozygous familial hypercholesterolaemia: A cross-sectional study	39
Intima-media thickness in treated and untreated patients with and without familial hypercholesterolemia: A systematic review and meta-analysis	38
Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromes	36
Impact of providing genetics-based future cardiovascular risk on LDL-C in patients with familial hypercholesterolemia	34
Niacin (Niacin) and clinical utility, don't be misled by recent niacin (Niacin) metabolite report	32
Hypertriglyceridemia during hospitalization independently associates with mortality in patients with COVID-19	32
Achievement of low-density lipoprotein cholesterol thresholds in very high-risk atherosclerotic cardiovascular disease	30
Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association	29
Socioeconomic Disparities in Dyslipidemia and Associated Complications: From the Latest National Database	28
Care of youth with lipid disorders: A brief provider survey	26
Effective treatment of statin- and ezetimibe-resistant hyperlipidemia in a patient with active membranous nephrotic syndrome using a PCSK9 inhibitor	25
Hypercoagulability or coronary artery disease? Polygenic risk score unveils the mystery	24

Genetic mutations and associated phenotypes in familial hypercholesterolemia: A biobank study	23
Healthcare utilization and expenditures among adults with severe hypertriglyceridemia in US clinical practice	23
Lipoprotein(a) concentrations across a global cross-sectional registry	22
Disparities in statin use among individuals with and without cancer history across atherosclerotic cardiovascular disease risk categories	20
Assessment of health disparities in secondary ASCVD risk prevention in the elderly population in Greece	20
Managing hypercholesterolemia in adults older than 75 years without a history of atherosclerotic cardiovascular disease: An Expert Clinical Consensus from the National Lipid Association and the Americ	19
Lomitapide in Pediatric Patients with Homozygous Familial Hypercholesterolemia – Analysis of Secondary and Safety Endpoints from the APH-19 Study	19
Table of Contents	19
Use of lipid-lowering therapies in patients with CKD and ASCVD: A 1-year update from GOULD	19
Association of Lipoprotein(a) with peri-coronary inflammation in persons with and without HIV infection	19
News from the NLA	18
From the Editors: Familial hypercholesterolemia: Still underdiagnosed and undertreated	18
The recognition and appreciation of Familial Hypercholesterolemia among Internal Medicine residents in the United States	18
*Real-World Experience with Inclisiran at a Large Academic Lipid Clinic	18
Triglyceride-rich lipoprotein sphingolipids are altered in primary hypertension: A pilot case-control study	17
Unique Case of Management of Severe Hypertriglyceridemia Secondary to Familial Chylomicronemia Syndrome	17
The Healthy Eating Assessment Tool (HEAT): A Aimplified 10-Point Assessment of CHILD-2 Dietary Compliance for Children with Dyslipidemia	17
⁎ Incidental Coronary Calcium on Non-Gated CT Scans of the Chest: A Stepwise Approach to Addressing Underreporting and Implementing Deep Learning	17
Characterization of Inclisiran Use in Real World: Prescription Data from Germany	17
Lipid profile and risk factors for neoatherosclerosis after drug-eluting stent implantation in acute coronary syndrome	16
A variant in the fibronectin (FN1) gene, rs1250229-T, is associated with decreased risk of coronary artery disease in familial hypercholesterolaemia	15
The Relationship of Alcohol Consumption and HDL Metabolism in the Multiethnic Dallas Heart Study	15
JCL Roundtable. Obesity, Diabetes, and Liver Disease in Relation to Cardiovascular Risk	15
Increased risk of ASCVD in women with PCOS is only partially mediated by incident metabolic comorbidities	15
Possible explanations for the common clinical familial hypercholesterolemia phenotypes in the Faroe Islands	15
Dyslipidemia among elderly patients with hyperuricemia and gout: Insights from the National Inpatient Sample	14
Elevated lipoprotein(a) levels attenuate LDL-C lowering in acute coronary syndrome patients treated with triple combination lipid-lowering therapy	14
Cardiovascular and pregnancy outcomes in women with hyperlipidemia with and without hypertension: A real-world evidence study	14
Acute pancreatitis events among patients with severe hypertriglyceridemia: A retrospective study	14
Promoting lipoprotein(a) awareness and testing for risk identification through outreach and teaching (PATRIOT-QI)	13
Clinical profile, genetic spectrum and therapy evaluation of 19 Chinese pediatric patients with lipoprotein lipase deficiency	13
Safety and effectiveness of evinacumab in an infant with homozygous familial hypercholesterolemia: A new renaissance for the very young?	13
Overcoming the real and imagined barriers to cholesterol screening in pediatrics	12
Treatment Patterns Among Early Inclisiran vs Anti–PCSK9 mAbs Users: A Retrospective Analysis of US Claims Databases	12
Editorial Board	11
*An Unsolved Case: FH or Sitosterolemia?	11
A Machine-Learning Algorithm using Claims Data to Identify Patients with Homozygous Familial Hypercholesterolemia (HoFH)	11
Carotenoids in familial hypobetalipoproteinemia disorders: Malabsorption in Caco2 cell models and severe deficiency in patients	11
Characteristics Associated with Inclisiran Initiation in Outpatient Physician Clinics	11
†Safety and Efficacy of Bempedoic Acid in Patients with Hypertension	11
Disparities Among Gender and Racial Groups in the Achievement of Optimal Lipid Levels in Patients Following Acute Coronary Syndrome	11
Comprehensive assessment of the combined impact of dyslipidemia and inflammation on chronic kidney disease development: A prospective cohort study	11
Fatty acid analysis in serum of patients with elevated lipoprotein(a) and cardiovascular disease undergoing lipoprotein apheresis	11
Management of Atherogenic Dyslipidemia in a Patient with LDL Discordance	11
The causal association between lipid-lowering strategies and risk of intracranial aneurysms: A drug-target Mendelian randomization study	10
Genetic association analyses highlight apolipoprotein B as a determinant of chronic kidney disease in patients with type 2 diabetes	10
Screening for Familial Hypercholesterolemia using Epic Secure Chat in Comparison to Epic Letter as Educational Outreach˄	10
Tailored Therapeutic Strategies for the Management of Chylomicronemia Syndrome	10
Genetic Testing Results in a Preventative Cardiology and Inherited Lipid Disorders Clinic	10
Awareness, diagnosis and treatment of heterozygous familial hypercholesterolemia (HeFH) – Results of a US national survey	10

Marked Hypoleptinemia precedes Overt Fat Loss in Immune Checkpoint Inhibitor-induced Acquired Generalized Lipodystrophy	10
The Family Heart Foundation™ Flag, Identify, Network, Deliver—Familial Hypercholesterolemia (FIND-FH™) Program and Collaborative Learning Network (CL	10
From the editors: Upcoming treatments for familial chylomicronemia syndrome: Agents that inhibit production of apolipoprotein CIII	10
Variation in lipoprotein(a) response to potent lipid lowering: The role of apolipoprotein (a) isoform size	10
Serum mature and furin-cleaved proprotein convertase subtilisin/kexin type 9 levels and their association with cardiovascular events in statin-treated patients with cardiovascular disease	10
†Cardiovascular Trials Over the Last 15 years: Analysis of the Characteristics and Trends of ClinicalTrials.gov Listings from 2008 to 2022	10
Impact of baseline demographics on lipid profile in patients with ACS: Unmasking hidden drivers	9
Racial Disparities and Modifiable Risk Factors in Black Patients with Familial Hypercholesterolemia	9
Multidisciplinary Management of Lipoprotein X-Induced Hyperlipidemia Secondary to Drug-Induced Liver Injury	9
Comparative cardiovascular outcomes of triple lipid-lowering therapy versus double therapy in patients with atherosclerotic cardiovascular disease: A	9
Association of cumulative low-density lipoprotein cholesterol exposure with vascular function	9
Accelerated Atherosclerosis in a Patient With Multifactorial Chylomicronemia Syndrome (MCS), Elevated Lp(a), APOE2/4 Genotype and Diabetes Mellitus.	9
Elevated Levels of Lp(a) are Associated with Circulating Levels of PCSK9 and Coronary Atherosclerosis as Detected by Cardiac Computed Tomography Angiography	9
Evaluating the underutilization of lipid-lowering therapy in Asian patients – A high-risk population	9
Hypertriglyceridemia induced Pancreatitis is associated with lower Inpatient Morbidity and Mortality compared to Biliary Pancreatitis	9
303 Incremental Benefit of Atherogenic Cholesterol Reduction with Obicetrapib Administered with Moderate-Intensity Statins	9
†Utility of AI-QCPA: Results of the Decisions for Treating Coronary Disease are Changed in Patients Evaluated with Quantified Plaque Analysis	9
Why Are Patients Presenting with STEMI Already on Statin Not Treated with Additional Aggressive Lipid-lowering Agents?	9
A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice	9
Concordance between LDL-C estimated by various formulas and directly measured LDL-C	8
Hourly 4-minute walking breaks from sitting following aerobic exercise reduce postprandial non-HDL cholesterol in healthy young adults - A randomized crossover trial	8
Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America	8
Metabolic syndrome predicts cardiovascular risk and mortality in familial hypercholesterolemia	8
Is Tangier disease a rare cause of premature ovarian insufficiency?: A case report	8
Clinical impact of ≥50% reduction of low density lipoprotein cholesterol following lipid lowering therapy on cardiovascular outcomes in patients with acute coronary syndrome	8
Time to benefit of intensive lipid lowering therapy in individuals with cardiovascular disease	8
GPIHBP1 autoantibody is an independent risk factor for the recurrence of hypertriglyceridemia-induced acute pancreatitis	8
Impact of small dense low-density lipoprotein cholesterol and triglyceride-rich lipoproteins on plaque rupture with ST-segment elevation myocardial infarction	8
† Safety and efficacy of obicetrapib in patients with heterozygous familial hypercholesterolemia	7
Functional profiling of LDLR variants: Important evidence for variant classification	7
Sex differences in the associations of HDL particle concentration and cholesterol efflux capacity with incident coronary artery disease in type 1 diabetes: The RETRO HDLc cohort study	7
Cardiovascular Mortality and Hospitalization Risk with LDL by CKD Stage in African-American and White US Veterans	7
CAC Scoring as an Index for Subclinical Carotid Atherosclerosis	7
^Polygenic risk score for coronary artery disease predicts atherosclerotic cardiovascular disease in familial hypercholesterolemia	7
The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint Clinical Perspective from the National Lipid Association and the American Society for Pre	7
Differences in Clinical outcomes between Non-Obese Hispanic and Asian populations Who have Hyperlipidemia	7
Effect of pharmacologic anti-atherosclerotic therapy on carotid intraplaque neovascularization: A systematic review	7
Early impact of 2018 AHA/ACC/Multisociety Cholesterol Guideline on lipid monitoring after statin initiation	7
Habitual fish oil supplementation, genetic susceptibility of kidney stones and the risk of new-onset kidney stones	7
Community pharmacist impact of addressing statin use in patients with diabetes	7
From the editor: Heroes in a historic time	7
Fellow Quality Improvement Project: Identification of High Risk CAD Patients and Referral to Newly Established Lipid Clinic, What are the Clinical Implications?	7
Table of Contents	7
Successful lipid-lowering in statin and PCSK9i intolerant patient with mixed hyperlipidemia: A case study of inclisiran as a therapeutic option.	6
From the editor: Lipidology resurgent as the pandemic wanes	6
Spotlight on Abetalipoproteinemia and Related Hypobetalipoproteinemia Disorders: A Simplified Nomenclature and Clinical Guidelines. †	6
Assessment of lipid-lowering therapies in high-risk patients with inflammatory joint diseases—Insights from a preventive cardio-rheuma clinic	6
Association between very high HDL-C levels and mortality: A systematic review and meta-analysis	6
Physician-reported reasons for not intensifying lipid-lowering therapy in patients with recent myocardial infarction	6
Hyperlipidemia and risk for preclampsia	6
Obicetrapib Lowers LDL-C in Patients Taking High Intensity Statins - Results from the ROSE Clinical Trial	6
Validation of physical examinations of tendon xanthomas and changes in the cutoff values of Achilles tendon thickness on radiography in the clinical criteria of heterozygous familial hypercholesterole	6
Evaluation of apolipoprotein A5 variants: A cohort of patients with severe hypertriglyceridemia from Turkiye	6
A novel homozygous nonsense variant of LMF1 in pregnancy-induced hypertriglyceridemia with acute pancreatitis	6
Lipoprotein(a) screening for cardiac allograft vasculopathy among heart transplant recipients	6
Treatment dilemmas faced by women of reproductive age with familial hypercholesterolemia: Case report	6
Cost-effectiveness of population-wide genomic screening for familial hypercholesterolemia in the United States	6
Dysbetalipoproteinamia: Implications for Pre-Conception, Pregnancy and Beyond	6
Evaluation of plasma phytosterols in sitosterolemia, their kindreds and hyperlipidemia subjects	6
Modifications on lipid profile and high-density lipoprotein function related to treatment with tofacitinib in female patients with rheumatoid arthritis: Impact of previous therapy with biological agen	6
Attrition of adipose: Type 2 familial partial lipodystrophy manifesting in severe premature CAD	6
Lipoprotein(a): Mirroring Familial Hypercholesterolemia	5
Elevated Serum Small Dense Low Density Lipoprotein Cholesterol and Lipoprotein(a) Levels in Preeclampsia	5
Cardiovascular Disease and Cholesterol Lowering Therapy in Women and Men with Molecularly Defined Heterozygous Familial Hypercholesterolemia from Brazil	5
No benefit of vitamin D supplementation on muscle function and health-related quality of life in primary cardiovascular prevention patients with statin-associated muscle symptoms: A randomized control	5
Remnant cholesterol and cardiovascular and all-cause mortality in Korean adults	5
Equitable Access to Screening and Lipid-Lowering Therapies in a Large Academic Center after Educational Interventions	5
†Food Compass Score is Inversely Related to Inflammatory Markers and Cardiovascular Disease Incidence: Results from the ATTICA Cohort Study (2002-2022)	5
Remnant cholesterol as a residual risk in atherosclerotic cardiovascular disease patients under statin-based lipid-lowering therapy: A post hoc analysis of the RACING trial	5
Differences in treatment strategies for LDL-cholesterol reduction in a university lipid clinic vs. standard care apart from the use of PCSK9 inhibitors	5
JCL Roundtable. Making prevention a priority	5
Differences in Clinical Outcomes between Non-Obese African American and Asian Populations Who have Hyperlipidemia	5
In memoriam: A tribute to Dr Scott M. Grundy	5
Sex differences in the presentation, treatment and outcomes of patients with homozygous familial hypercholesterolemia	5
What's next for lipoprotein(a)? A National Lipid Association report from an Expert Panel Discussion	5
Comprehensive analysis of Chinese patients with non-LPL familial chylomicronemia syndrome: Genetic variants, dietary interventions, and clinical insights	4
Carotid sheath xanthoma: A rare manifestation of lipid disorders	4
† Higher Cardiovascular Event Rates for High-Risk Americans Who Did Not Meet 2018 Multidisciplinary Guideline on the Management of Blood Cholesterol Thresholds	4
Association of inclisiran initiation on oral antilipemic therapy discontinuation rates	4
*Sitosterolemia due to a new combination of ABCG8 variants presenting as hemolytic anemia and thrombocytopenia: A case report	4

Editorial Board	4
Effect of Dexamethasone on Modulating Lp(a) Levels in COVID-19 Pneumonia	4
Dedicated training in obesity management: A pathway to better physician practice	4
Race/ethnicity and socioeconomic status affect the assessment of lipoprotein(a) levels in clinical practice	4
*A Novel ABCG8 Variant and Apo(A) Short Isoform Associated with Premature Atherosclerosis and Familial Hypercholesterolemia Phenocopy.	4
†Plozasiran (ARO-APOC3), an Investigational RNAi, Demonstrates Deep and Durable TG Reductions in Patients With SHTG, SHASTA-2 Final Results	4
The Food Compass Score is Negatively Related to the Activity of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) in Healthy Adults.	4
Corrigendum to “Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial” [Journal of Clinical Lipid	4
Genomic study of maternal lipid traits in early pregnancy concurs with four known adult lipid loci	4
Long-term monitoring of LPL gene replacement therapy: A lexicon of lessons for gene editing or oligonucleotide-based lipid lowering treatments	4
Association between apolipoprotein B and obesity: A cross-sectional analysis of NHANES data	4
†Efficacy and Safety of Bempedoic Acid in Patients with Metabolic Syndrome	4
Treatment Target Achievement in Patients with Familial Hypercholesterolemia: A Real-World Descriptive Study	4
The analysis of the breakpoint of large rearrangements of LDLR gene in a Taiwanese cohort of patients with familial hypercholesterolemia	4
In memoriam, Avedis Khachadurian 1926 - Sept 22,2022	4
Moderate Alcohol Consumption and Lipoprotein Subfractions: A Systematic Review of Intervention and Observational Studies	4
Disparities in access to pharmacotherapies for weight loss and cardiovascular prevention	4
+Racial Inequities in Coronary Artery Calcium Screening and Follow-up	4
Association of lipid-lowering drugs with gut microbiota: A Mendelian randomization study	4
Concerns regarding NMR lipoprotein analyses performed on the Nightingale heath platform – Focus on LDL subclasses	4
† Cholesterol treatment trends from 2014 - 2023 in 3 Million US individuals with ASCVD: a retrospective cohort analysis using the Family Heart DatabaseTM	4
^Sex Disparities in the Treatment and Outcomes of Familial Hypercholesterolemia	4
From the editor: A compendium of lipidology progress	4
† Effect of plozasiran targeting APOC3 on lipoprotein particle number and size measured by NMR in patients with hypertriglyceridemia	4
Oral semaglutide and reduction in major adverse cardiovascular events	4
Pancreatitis polygenic risk score is associated with acute pancreatitis in multifactorial chylomicronemia syndrome	4
Addressing residual risk beyond statin therapy: New targets in the management of dyslipidaemias–A report from the European Society of Cardiology Cardiovascular Round Table	4
Negative LDL-C levels with Detectable Apolipoprotein B: Surrogate Markers of Atherosclerotic Disease and Cardiac Event Risk	4
†Obicetrapib Does Not Accumulate in Adipose Tissue: Results from Studies in Man and Non-human Primates	3
Identification of High Cardiovascular Disease Risk Individuals in an Underserved Patient Population Clinic	3
Utilizing gamification to educate internal medicine residents on managing lipids in patients with inflammatory conditions	3
Pegylated-Asparaginase Induced Severe Hypertriglyceridemia in an Adult with Acute B-cell Lymphoblastic Leukemia	3
Diagnosis and Management of Familial Dysbetalipoproteinemia in a Patient with Apo E2/E2 Genotype	3
Healthcare costs among acute pancreatitis patients with severe hypertriglyceridemia	3
Improving adherence with lipid-lowering agents	3
Attitudes and barriers to lipoprotein(a) testing: A survey of providers at the University of Pennsylvania Health System	3
CME Activity Highlights the Improvement in Clinician's Knowledge and Competence about Treatment Choices for LDL-C Lowering Post-MI	3
Composition and distribution of lipoproteins after evolocumab in familial dysbetalipoproteinemia: A randomized controlled trial	3
Improving cholesterol management in high-risk primary prevention patients: An evidence-based case series	3
Is hypertriglyceridemia a reliable indicator of cholesterol-depleted Apo B particles?	3
Prevalence of severe hypertriglyceridemia and pancreatitis in familial partial lipodystrophy type 2	3
Unveiling Compound Heterozygous Familial Hypercholesterolemia	3
Adherence to lipid monitoring and its impact on treatment intensification of LDL-C lowering therapies at an urban academic medical center	3
Racial disparities in LDL-C control, ASCVD risk reclassification by statin use, coronary artery calcium scores, and the Pooled Cohort Equation	3
Lipids management in patients with diabetes mellitus: Experience from a cohort study in Greece.	3
Effect of hormone replacement therapy on in-hospital outcomes of ischemic stroke in older women with dyslipidemia: A large-scale nationwide analysis	3
Predicting resilience in heterozygous familial hypercholesterolaemia: A cohort study of octogenarian patients	3
Severe Hypertriglyceridemia as a Cause of Arterial Thrombosis with Peripheral Embolic Complications.	3
Association of lipoprotein(a) with peripheral artery disease and outcomes: A propensity-matched retrospective analysis	3
Impact of conducting a genetic study on the management of familial hypercholesterolemia	3
Detailed Family History of Premature Atherosclerotic Cardiovascular Disease to Guide Lipoprotein(a) Testing: The Multi-Ethnic Study of Atherosclerosis	3
Editorial Board	3
Premature coronary artery disease in the absence of traditional risk factors - a hidden dilemma	3
Severe Medication Induced Dyslipidemia in an Adult with Breast Cancer	3
Timing of PCSK9i Initiation and Its Relationship with Clinical Outcomes in US Patients with Prior Cardiovascular Events: A Claims Database Analysis	3
One size doesn't fit all: A dose-dependent twist in PCSK9 monoclonal antibody therapy	3
A Single-Dose, Randomized, Open-Label, Two-Period Crossover Bioequivalence Study in Healthy Adults Comparing Two Subcutaneous Formulations of Olezarsen: (Vial and Autoinjector) at Two Dose Levels	3
Evaluation of Lp(a) for cardiovascular disease risk prediction in the veteran's health administration	3
A case of lipoprotein glomerulopathy due to the pathogenic APOE Las Vegas variant c.509C > A: p. (Ala170Asp)	3
Racial Variations in SGLT2 Inhibitor Prescriptions	3
Successful pregnancy outcome in a woman with cholesteryl ester storage disease treated with enzyme replacement therapy	3
Impact of PCSK9 monoclonal antibody inhibitors on Lp(a) reduction in African Americans with elevated Lp(a)	2
Small interfering ribonucleic acid for cholesterol lowering – Inclisiran	2
The effect of adjusting LDL-cholesterol for Lp(a)-cholesterol on the diagnosis of familial hypercholesterolaemia	2
Mediation effect of metabolic factors and inflammation on the association of serum uric acid with serum proprotein convertase subtilisin/kexin type 9 levels	2
Unfavorably altered lipid profile in women with primary ovarian insufficiency	2
Association of Systemic Inflammation with Lipid Profiles and Management in Patients with Rheumatoid Arthritis	2
Forty year follow-up of three patients with complete absence of apolipoprotein B-containing lipoproteins	2
Multiple Myeloma and Hyperlipidemia - coincidence or related?	2
Reference values for the triglyceride to high-density lipoprotein ratio and its association with cardiometabolic diseases in a mixed adult population: The ELSA-Brasil study	2
News from NLA	2
Triglyceride-lowering and anti-inflammatory mechanisms of omega-3 polyunsaturated fatty acids for atherosclerotic cardiovascular risk reduction	2
Patients with Dyslipidemia and Chronic Kidney Disease Affected by Non-Alcoholic Fatty Liver Disease Have higher Mortality and Worse Clinical Outcomes, Nation-Wide Study	2
Impact of value-based comprehensive medication management on statin prescribing in patients with type 2 diabetes mellitus	2
Prevalence, pattern, and correlates of dyslipidemia in Bangladeshi individuals	2
Adherence to statin treatment in patients with familial hypercholesterolemia: A dynamic prediction model	2
JCL Roundtable: Dietary recommendations and intermittent fasting and time-restricted eating	2
The Value of Lipid Testing in Recognizing Residual Risk	2
Circulating Levels of PCSK9, ANGPTL3 and Lp(a) in Stage III Breast Cancers	2
Ordering Trends and Report Outcomes for Lipid Genes on a Comprehensive Cardiovascular Genetics Menu	2
*Pericardial and Pleural Effusions after Evolocumab in a Patient with Severe Familial Hypercholesterolemia	2
Acknowledgement of Referees	2
Guideline based eligibility for primary prevention statin therapy – Insights from the North India ST-elevation myocardial infarction registry (NORIN-STEMI)	2
The Outcome of Percutaneous Coronary Intervention in Prediabetes Patients: A Nationwide Analysis	2
Dyslipidemia management in women of reproductive potential: An Expert Clinical Consensus from the National Lipid Association	2
Improved arterial inflammation with high dose omega-3 fatty acids in patients with elevated lipoprotein(a): Selective effect of eicosapentaenoic acid?	2
LpX and LpZ associated Hypercholesterolemia in a Patient with Primary Sclerosing Cholangitis – a Case Report	2
High burden of disease in patients with homozygous familial hypercholesterolemia despite recent advances in therapies and updated guidelines: A real-world study	2
From the Editors: New concepts in obesity and cardiovascular disease	2
Time-Averaged LDL-C Lowering with Evolocumab: Pooled Analysis of Phase 2 Trials	2
Rare genetic cerebrotendinous xanthomatosis (CTX) cases without cholestanol elevation but with prominent cholesterol-rich tendon xanthomas	2
Free fatty acids and heart failure in the Multi-Ethnic Study of Atherosclerosis (MESA)	2
News from NLA	2
Lipoprotein(a), metabolic profile and new-onset type 2 diabetes in patients with familial combined hyperlipidemia: A 9 year follow-up study	2
Elevated LDL-cholesterol levels among lean mass hyper-responders on low-carbohydrate ketogenic diets deserve urgent clinical attention and further research	2